C-POST
07 Dec 2020
Trial Summary
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Acronym:
C-POST
ACTRN/NCT /ethics:
NCT03969004
Scientific title:
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Sponsor / Cooperative group:
Regeneron Pharmaceuticals
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2019-06-04 |
| Anticipated End Date | 2026-11-02 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Brian Stein |
| Recruitment Status | Recruiting |